FDA Grants Temab-A Breakthrough Therapy Designations

AbbVie's telisotuzumab adizutecan receives two designations for advanced colorectal and lung cancers.

Updated on Nov. 3, 2026 in Cancer

Vector editorial illustration of three amber glass vials and a metal pipette on a pale surface, evoking a cancer drug under regulatory review. — The FDA granted Breakthrough Therapy Designations to AbbVie's investigational telisotuzumab adizutecan, known as Temab-A, for two advanced cancers. AI Illustration. Upload story photo >

The FDA granted Breakthrough Therapy Designations to AbbVie's telisotuzumab adizutecan (Temab-A), one for use with bevacizumab in refractory metastatic colorectal cancer and another as standalone treatment for certain non-small cell lung cancers. The designations are primarily supported by results from the first-in-human M21-404 study.

Why it matters

The Breakthrough Therapy designation program is intended to speed development and review of investigational medicines for serious conditions. Colorectal and lung cancers remain major causes of cancer-related deaths worldwide, and preliminary clinical evidence suggests Temab-A may offer substantial improvement over available treatments.

The designations rest on first-in-human data from the M21-404 study of advanced solid tumours, which is an early-phase trial. The source does not provide response rates or survival figures, and larger studies would be needed to confirm benefit.

The players

AbbVie

AbbVie is a global biopharmaceutical company that develops and markets treatments across immunology, oncology, and neuroscience.

U.S. Food and Drug Administration (FDA)

The FDA is the U.S. federal agency responsible for regulating and approving drugs, including granting Breakthrough Therapy Designations.

The details

Temab-A is a next-generation antibody-drug conjugate that targets the c-Met protein, which is found at increased levels in several solid tumours. It combines a humanised monoclonal antibody with a topoisomerase I inhibitor payload, a design intended to deliver the drug to target cells while limiting its release into the wider body.

November 3, 2026: AbbVie published the announcement of the Temab-A designations.

Health Landscape

The FDA's Breakthrough Therapy Designation program, created to accelerate review of drugs for serious conditions, is being applied here to an antibody-drug conjugate targeting c-Met. The designations extend that program into two cancer types where treatment options remain limited.

For patients with refractory colorectal or certain non-small cell lung cancers, Temab-A represents a potential future option, though it is not yet an approved treatment. Patients considering experimental therapies should discuss trial enrollment and eligibility with their oncologists.

The takeaway

Breakthrough designations signal regulatory confidence in early data but do not establish efficacy or approval. Patients should watch for results from later-stage trials before expecting Temab-A in clinical practice.